National MS Society: Experimental Therapy Targeting Cells Infected With Epstein-Barr Virus Fails to Show Benefit, Says Company
November 14, 2023
November 14, 2023
NEW YORK, Nov. 14 (TNSres) -- The National Multiple Sclerosis Society issued the following news:
Atara Biotherapeutics, Inc. announced that its experimental therapy called ATA188 failed to reverse disability for people with progressive MS after a 12-month phase 2 clinical trial. The treatment also showed no benefits on MRIs or other tests. The company had anticipated that targeting and eliminating immune cells infected with the Epstein-Barr virus (EBV) would change the course of pro . . .
Atara Biotherapeutics, Inc. announced that its experimental therapy called ATA188 failed to reverse disability for people with progressive MS after a 12-month phase 2 clinical trial. The treatment also showed no benefits on MRIs or other tests. The company had anticipated that targeting and eliminating immune cells infected with the Epstein-Barr virus (EBV) would change the course of pro . . .